Breaking News
Keegan Nees, IMMY, on Fungal Infection Diagnostics
We caught up with Keegan Nees, a Product Marketing Strategist from IMMY, at ECCMID, who discusses his company’s focus on fungal infection diagnostics. He explains that IMMY is dedicated to developing innovative solutions for the accurate and timely diagnosis of fungal infections.
Nees emphasizes the significance of fungal infections, highlighting their prevalence and the challenges they pose in terms of diagnosis and treatment. He emphasizes that early and accurate detection is crucial for effective management of these infections.
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more
Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients
Eloxx Pharmaceuticals, a leader in ribosomal RNA-targeted genetic therapies for rare diseases, have announced the […]
Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS
Verge Genomics, a clinical-stage biotechnology company transforming drug discovery using artificial intelligence and human data, […]
Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic
Vyriad announces an expansion of a Phase 1 investigator-initiated trial at Mayo Clinic evaluating the […]
Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Alentis Therapeutics, the clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ […]
Acadia Pharmaceuticals Announces Phase 3 Development Candidate ACP-101 for Prader-Willi Syndrome
Acadia Pharmaceuticals today announced the addition of a new Phase 3 development candidate to its […]
Future Fields and Jenthera Therapeutics Collaborate to Develop Novel Protein for the Delivery of Cancer Biologics
Future Fields, a pioneering biotechnology company that has built the world’s first synthetic biology system […]
Heligenics Unveils A First-Of-Its-Kind Precision Prescription Test For Breast Cancer Therapeutics
Heligenics, a cutting-edge biotech company, announces a first-of-its-kind precision genetic test to select among drugs […]
Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients
Eloxx Pharmaceuticals, a leader in ribosomal RNA-targeted genetic therapies for rare diseases, have announced the […]
Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS
Verge Genomics, a clinical-stage biotechnology company transforming drug discovery using artificial intelligence and human data, […]
DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board
DEM BioPharma, an immune-oncology company developing therapies that target signals on cancer cells and myeloid […]
Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera
Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled receptors (GPCRs), today […]
Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic
Vyriad announces an expansion of a Phase 1 investigator-initiated trial at Mayo Clinic evaluating the […]
Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders
Astellas Pharma and Cullgen have announced a research collaboration and exclusive option agreement to discover […]
Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program
Auxilius Pharma has consolidated its funding of $1 Million for developing its lead asset, AUX-001, […]